Antabio Awarded $4.4 Million from CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis Patients

  03 January 2020

Antabio SAS, the biopharmaceutical company focused on developing a
broad pipeline of antibacterial treatments against life threatening WHO critical priority pathogens, announces that it has been awarded up to $4.4 million in a second tranche funding from CARB-X, the global nonprofit partnership dedicated to tackling the global rising threat of drug-resistant bacteria. The funding is to support the development of Antabio’s novel small molecule candidate for the treatment of Pseudomonas
aeruginosa infections in Cystic Fibrosis (CF) patients.

Further reading: Antabio
Author(s): Antabio
Smart Innovations  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!